File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis

TitleA clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis
Authors
Issue Date1990
Citation
Asian Pacific Journal Of Allergy And Immunology, 1990, v. 8 n. 2, p. 109-115 How to Cite?
AbstractThe efficacy of budesonide, terfenadine and a combination of budesonide and oxymetazoline in the treatment of perennial rhinitis was evaluated by a double blind, parallel group study. Adult patients with perennial rhinitis were randomized into three groups. Group 1 patients received budesonide nasal aerosol 400 μg/day for 21 days and oxymetazoline nasal drops for the first three days. Group 2 and 3 patients received budesonide 400 μg/day and terfenadine tablet 60 mg twice/day respectively. Nasal symptoms were assessed by the patients before and daily during the treatment period using a simple scoring system. One hundred and forty-two patients were recruited and 130 completed the study. Budesonide, but not terfenadine, significantly reduced all nasal symptoms from baseline (p<0.05). Terfenadine could significantly relieve the nasal blockage (p<0.05) more than other nasal symptoms. Budesonide with or without oxymetazoline nasal drops provided a better control of nasal symptoms than terfenadine (p<0.05). Budesonide with oxymetazoline for the first three days showed a faster relief of nasal blockage than budesonide alone (p<0.05). Mild and transient adverse effects were encountered in all three groups. It is concluded that nasal symptoms of perennial rhinitis are more adequately controlled by budesonide than by terfenadine.
Persistent Identifierhttp://hdl.handle.net/10722/172635
ISSN
2015 Impact Factor: 1.269
2015 SCImago Journal Rankings: 0.560
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, SKen_US
dc.contributor.authorWei, WIen_US
dc.contributor.authorVan Hasselt, CAen_US
dc.contributor.authorSham, CLen_US
dc.contributor.authorWoo, Jen_US
dc.contributor.authorChoa, Den_US
dc.contributor.authorEngzell, UCGen_US
dc.date.accessioned2012-10-30T06:23:56Z-
dc.date.available2012-10-30T06:23:56Z-
dc.date.issued1990en_US
dc.identifier.citationAsian Pacific Journal Of Allergy And Immunology, 1990, v. 8 n. 2, p. 109-115en_US
dc.identifier.issn0125-877Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/172635-
dc.description.abstractThe efficacy of budesonide, terfenadine and a combination of budesonide and oxymetazoline in the treatment of perennial rhinitis was evaluated by a double blind, parallel group study. Adult patients with perennial rhinitis were randomized into three groups. Group 1 patients received budesonide nasal aerosol 400 μg/day for 21 days and oxymetazoline nasal drops for the first three days. Group 2 and 3 patients received budesonide 400 μg/day and terfenadine tablet 60 mg twice/day respectively. Nasal symptoms were assessed by the patients before and daily during the treatment period using a simple scoring system. One hundred and forty-two patients were recruited and 130 completed the study. Budesonide, but not terfenadine, significantly reduced all nasal symptoms from baseline (p<0.05). Terfenadine could significantly relieve the nasal blockage (p<0.05) more than other nasal symptoms. Budesonide with or without oxymetazoline nasal drops provided a better control of nasal symptoms than terfenadine (p<0.05). Budesonide with oxymetazoline for the first three days showed a faster relief of nasal blockage than budesonide alone (p<0.05). Mild and transient adverse effects were encountered in all three groups. It is concluded that nasal symptoms of perennial rhinitis are more adequately controlled by budesonide than by terfenadine.en_US
dc.languageengen_US
dc.relation.ispartofAsian Pacific Journal of Allergy and Immunologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAerosolsen_US
dc.subject.meshAgeden_US
dc.subject.meshBenzhydryl Compounds - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBronchodilator Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBudesonideen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHistamine H1 Antagonists - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNasal Decongestants - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshOxymetazoline - Administration & Dosageen_US
dc.subject.meshPregnenediones - Administration & Dosageen_US
dc.subject.meshRhinitis, Allergic, Perennial - Drug Therapyen_US
dc.subject.meshTerfenadineen_US
dc.titleA clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitisen_US
dc.typeArticleen_US
dc.identifier.emailWei, WI: hrmswwi@hku.hken_US
dc.identifier.authorityWei, WI=rp00323en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1709020-
dc.identifier.scopuseid_2-s2.0-0025612849en_US
dc.identifier.volume8en_US
dc.identifier.issue2en_US
dc.identifier.spage109en_US
dc.identifier.epage115en_US
dc.identifier.isiWOS:A1990EX85100007-
dc.publisher.placeThailanden_US
dc.identifier.scopusauthoridLau, SK=25932968400en_US
dc.identifier.scopusauthoridWei, WI=7403321552en_US
dc.identifier.scopusauthoridVan Hasselt, CA=7103394173en_US
dc.identifier.scopusauthoridSham, CL=6701587015en_US
dc.identifier.scopusauthoridWoo, J=27268094700en_US
dc.identifier.scopusauthoridChoa, D=6602269197en_US
dc.identifier.scopusauthoridEngzell, UCG=6701817437en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats